Atrion (NASDAQ:ATRI) Sets New 1-Year Low at $671.00

Shares of Atrion Co. (NASDAQ:ATRI) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $671.00 and last traded at $671.00, with a volume of 2894 shares trading hands. The stock had previously closed at $682.20.

ATRI has been the topic of several research reports. ValuEngine raised shares of Atrion from a “sell” rating to a “hold” rating in a report on Friday, November 8th. BidaskClub lowered shares of Atrion from a “sell” rating to a “strong sell” rating in a report on Thursday, February 6th.

The company has a market capitalization of $1.27 billion, a PE ratio of 33.56 and a beta of 0.15. The company’s fifty day moving average is $716.76 and its 200-day moving average is $749.87.

In other Atrion news, Chairman Emile A. Battat bought 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was bought at an average cost of $686.25 per share, for a total transaction of $686,250.00. Following the completion of the transaction, the chairman now directly owns 148,673 shares of the company’s stock, valued at approximately $102,026,846.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John P. Stupp, Jr. sold 277 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $711.47, for a total transaction of $197,077.19. Following the transaction, the director now owns 5,844 shares of the company’s stock, valued at $4,157,830.68. The disclosure for this sale can be found here. 22.07% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Capital Analysts LLC lifted its position in Atrion by 2.4% during the fourth quarter. Capital Analysts LLC now owns 645 shares of the medical instruments supplier’s stock valued at $485,000 after purchasing an additional 15 shares during the period. FMR LLC lifted its position in Atrion by 277.8% during the fourth quarter. FMR LLC now owns 34 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 25 shares during the period. California State Teachers Retirement System lifted its position in Atrion by 1.9% during the third quarter. California State Teachers Retirement System now owns 2,246 shares of the medical instruments supplier’s stock valued at $1,750,000 after purchasing an additional 42 shares during the period. Schroder Investment Management Group lifted its position in Atrion by 11.5% during the fourth quarter. Schroder Investment Management Group now owns 522 shares of the medical instruments supplier’s stock valued at $392,000 after purchasing an additional 54 shares during the period. Finally, Envestnet Asset Management Inc. lifted its position in Atrion by 25.2% during the third quarter. Envestnet Asset Management Inc. now owns 403 shares of the medical instruments supplier’s stock valued at $314,000 after purchasing an additional 81 shares during the period. Institutional investors own 66.17% of the company’s stock.

About Atrion (NASDAQ:ATRI)

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Read More: Debt-To-Equity Ratio

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.